Navigation Links
Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinson's Disease Target LRRK2
Date:12/16/2010

LA JOLLA, Calif., Dec. 16, 2010 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S (Lundbeck) utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2.  Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

"We are pleased that our expertise in protein expression, purification and crystallization has been recognized by a leader in CNS drug discovery and look forward to a long and productive relationship with Lundbeck," says Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia.

"Zenobia has a strong structural biology team and the lead on this important Parkinson's target.  We are pleased to be working with them," says Klaus Baek Simonsen, Head of Discovery Chemistry at H. Lundbeck A/S.

Under the agreement, Zenobia will complete x-ray crystal structures of wild-type and the Parkinson's disease-associated mutant, G2019S, in complex with Lundbeck lead compounds.  Zenobia retains all rights and ownership of the LRRK2 structure and to their internal LRRK2 chemistry program.

About Zenobia

Zenobia provides a commercial fragment library, and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia's internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating illnesses for which there is no disease altering treatment such as Parkinson's disease and pediatric neuroblastoma.

www.zenobiatherapeutics.com

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.


'/>"/>
SOURCE Zenobia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
2. Cell Therapeutics, Inc. (CTI) to Report Third Quarter 2010 Financial Results on October 28
3. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
4. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
5. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
6. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
7. ActiveCare, Inc. Announces Strategic Relationship With Vista Therapeutics, Inc. in Developing Nano Biosensors for the Elderly
8. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
9. Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
10. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
11. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):